Neuraceq Automated Synthesizer Synthera® (Neuraceq Synthera®) Received Shonin Approval in Japan

​

Piramal Imaging S.A. today announced that it has received Shonin (medical device) approval from the Ministry of Health, Labor and Welfare (MHLW) of Japan for Neuraceq Automated Synthesizer Synthera® (Neuraceq Synthera®). The approval, obtained through Piramal Imaging's service partner, SCETI K.K., Tokyo, enables Japanese hospitals and imaging centers access to the equipment needed for on-site manufacturing of the β-amyloid imaging agent florbetaben 18F, which is approved in the EU, U.S. and South Korea under the brand name Neuraceq™.

To read more please visit http://www.newswire.ca/news-releases/neuraceq-automated-synthesizer-synthera-neuraceq-synthera-received-shonin-approval-in-japan-599475051.html

Source: Piramal Enterprises Ltd.